Cyclin D3 expression in primary Ta/T1 bladder cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cyclin D3 deregulation is implicated in bladder cancer.
• Its prognostic significance in early-stage bladder tumors (Ta/T1) requires clarification.
• Understanding cell cycle regulators is crucial for predicting bladder cancer progression.

Purpose of the Study:

• To investigate the prognostic significance of cyclin D3 expression in Ta/T1 bladder cancer.
• To assess the association of cyclin D3 with cell cycle regulators (p53, p21Waf1, p27kip1, cyclin D1) and tumor proliferation (ki67-MIB1).
• To determine the relationship between cyclin D3 and 9p21 loss of heterozygosity (LOH) and its impact on progression-free survival.

Main Methods:

• Immunohistochemistry and western blotting were used to assess cyclin D3 expression.
• Expression of other cell cycle regulators and proliferation markers (ki67-MIB1) were evaluated.
• Loss of heterozygosity at the 9p21 locus was analyzed using microsatellite markers.

Main Results:

• Cyclin D3 overexpression correlated with larger tumor size and higher tumor proliferation.
• Mean cyclin D3 expression increased with higher tumor grade in both stage Ta and T1 tumors.
• Cyclin D3 was identified as an independent predictor of progression-free survival, with a higher risk ratio than tumor size and cyclin D1.

Conclusions:

• Cyclin D3 expression is a significant independent predictor of progression-free survival in patients with Ta/T1 bladder carcinomas.
• Cyclin D3 overexpression is associated with adverse prognostic factors like tumor size and proliferation.
• These findings highlight the clinical relevance of cyclin D3 in managing early-stage bladder cancer.